There's Reason For Concern Over Natera, Inc.'s (NASDAQ:NTRA) Price
May 18
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 28, 2025
DataAggregated Company Financials
Companies567
- 7D-1.0%
- 3M-8.8%
- 1Y-10.4%
- YTD-5.2%
Over the last 7 days, the Biotech industry has dropped 1.0%, driven by Regeneron Pharmaceuticals declining 1.9%. Overall the industry is down 10% in 12 months. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 28 May 2025 | US$911.8b | US$155.9b | -US$24,111,099,148.63 | 16x | -37.8x | 5.8x |
| Fri, 25 Apr 2025 | US$790.7b | US$119.2b | -US$36,562,802,211.15 | 20x | -21.6x | 6.6x |
| Sun, 23 Mar 2025 | US$827.4b | US$118.6b | -US$36,836,383,348.69 | 20.4x | -22.5x | 7x |
| Tue, 18 Feb 2025 | US$842.1b | US$116.6b | -US$36,838,458,362.91 | 17.6x | -22.9x | 7.2x |
| Thu, 16 Jan 2025 | US$933.0b | US$149.4b | -US$26,288,358,151.10 | 17x | -35.5x | 6.2x |
| Sat, 14 Dec 2024 | US$1.0t | US$150.0b | -US$26,499,023,924.94 | 16.6x | -37.8x | 6.7x |
| Mon, 11 Nov 2024 | US$1.1t | US$149.6b | -US$27,286,902,976.61 | 16.5x | -40.7x | 7.4x |
| Wed, 09 Oct 2024 | US$878.9b | US$113.1b | -US$35,894,198,277.00 | 20.5x | -24.5x | 7.8x |
| Fri, 06 Sep 2024 | US$891.3b | US$113.1b | -US$35,694,163,155.93 | 22.9x | -25x | 7.9x |
| Sun, 04 Aug 2024 | US$1.2t | US$165.8b | -US$32,803,544,510.84 | 25.9x | -36.7x | 7.3x |
| Tue, 02 Jul 2024 | US$1.1t | US$164.4b | -US$27,968,148,950.64 | 28.8x | -41.1x | 7x |
| Thu, 30 May 2024 | US$1.1t | US$164.6b | -US$26,666,955,066.31 | 26.8x | -41.5x | 6.7x |
| Sat, 27 Apr 2024 | US$1.1t | US$164.6b | -US$27,388,073,165.09 | 22.6x | -39.1x | 6.5x |
| Mon, 25 Mar 2024 | US$1.2t | US$164.3b | -US$23,931,097,513.35 | 21.4x | -48.6x | 7.1x |
| Wed, 21 Feb 2024 | US$1.2t | US$169.2b | -US$20,429,726,157.04 | 15.8x | -56.6x | 6.8x |
| Fri, 19 Jan 2024 | US$1.4t | US$204.7b | -US$22,508,448,136.00 | 18.3x | -63.1x | 6.9x |
| Sun, 17 Dec 2023 | US$1.4t | US$204.7b | -US$22,119,635,723.00 | 19.2x | -61x | 6.6x |
| Tue, 14 Nov 2023 | US$1.2t | US$204.5b | -US$21,994,312,170.00 | 18.6x | -54.7x | 5.9x |
| Thu, 12 Oct 2023 | US$1.3t | US$207.4b | -US$13,067,336,949.00 | 17.4x | -97.2x | 6.1x |
| Sat, 09 Sep 2023 | US$1.3t | US$207.5b | -US$12,633,744,533.00 | 17.4x | -100.7x | 6.1x |
| Mon, 07 Aug 2023 | US$1.3t | US$210.2b | -US$10,135,599,050.00 | 15.6x | -124.3x | 6x |
| Wed, 05 Jul 2023 | US$1.1t | US$186.2b | -US$16,059,041,068.00 | 13.4x | -69.8x | 6x |
| Fri, 02 Jun 2023 | US$1.1t | US$186.0b | -US$15,979,792,463.00 | 11.3x | -69.9x | 6x |
| Sun, 30 Apr 2023 | US$1.2t | US$197.1b | -US$6,664,428,484.00 | 13.7x | -173.7x | 5.9x |
| Tue, 28 Mar 2023 | US$1.1t | US$199.4b | -US$3,654,764,713.00 | 13.7x | -309.6x | 5.7x |
| Thu, 23 Feb 2023 | US$1.1t | US$203.1b | US$67.8m | 16.3x | 16824.6x | 5.6x |
| Sat, 21 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.4x | 655.3x | 5.7x |
| Mon, 19 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 713.2x | 5.7x |
| Wed, 16 Nov 2022 | US$1.1t | US$202.3b | US$1.3b | 14.5x | 861.9x | 5.6x |
| Fri, 14 Oct 2022 | US$1.1t | US$206.1b | US$5.4b | 15.4x | 196.5x | 5.1x |
| Sun, 11 Sep 2022 | US$1.1t | US$206.7b | US$5.8b | 15.6x | 188.1x | 5.3x |
| Tue, 09 Aug 2022 | US$1.1t | US$208.3b | US$5.8b | 16.6x | 193.7x | 5.4x |
| Thu, 07 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.1x | 99.2x | 5.1x |
| Sat, 04 Jun 2022 | US$1.0t | US$212.8b | US$11.3b | 16.4x | 88.7x | 4.7x |
Price to Earnings Ratio
88.7x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.30% | |
| Healthcare | -2.18% | |
| Biotech | -1.03% | |
| Biotech | -1.03% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$279.45 | 3.0% +US$4.4b | -5.7% | PE25.3x | |
| ONC BeiGene | US$238.31 | 0.6% +US$2.6b | 55.6% | PS6.8x | |
| ABBV AbbVie | US$185.72 | 0.5% +US$1.5b | 19.6% | PE79x | |
| SMMT Summit Therapeutics | US$25.64 | 5.1% +US$928.3m | 972.8% | PB55.3x | |
| MRUS Merus | US$50.80 | 15.4% +US$470.0m | -7.4% | PS64.2x |